In some patients, BCMA-negative relapse has been associated with upregulation of annexin A1 (ANXA1), a molecule that promotes myeloma growth and disrupts CAR-T targeting; preclinical inhibition of ANXA1 restores CAR-T sensitivity [128]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.